Source notes

Contraception works better as care when people can choose a suitable method and obtain help using it. This 2024 guidance addresses starting contraception, managing side effects, and avoiding unnecessary barriers. Its recommendations combine systematic evidence reviews with expert and patient input. For example, pooled results from three randomized trials found that people self-injecting a particular contraceptive formulation were 27% more likely to continue using it than those receiving provider-administered injections. Pregnancy rates were low and did not differ in the studies reporting them. Continuation, however, is not the same outcome as greater contraceptive effectiveness.

The central principle is informed, voluntary choice. A method's effectiveness matters alongside side effects, access, personal preferences, and the ability to stop or change it. The guidance supports offering self-injection as an additional option while keeping provider-administered care available. It also separates necessary safety checks from tests that need not delay contraception for otherwise healthy patients, with requirements differing by method.

How Does This Show Up in Real Life?

Someone considering an intrauterine device can discuss a pain-management plan before placement rather than assume pain must simply be tolerated. Someone troubled by bleeding with an implant can discuss treatment, continued use, or removal according to their preferences. The guidance also supports providing up to a year's supply of contraceptive pills when that fits anticipated use and the person's wishes, reducing repeated supply barriers. These examples support a conversation with a clinician rather than a universal prescription. Starting rules, backup protection, and what to do after missed doses depend on the exact method and circumstances. Most hormonal methods and intrauterine devices do not prevent sexually transmitted infections. The document also emphasizes that testosterone use should not be relied on to prevent pregnancy.

Evidence quality varies across questions, and some recommendations rely on indirect evidence when direct studies are absent. Not all populations are well represented. Benefits of treatments for implant-related bleeding may disappear after treatment stops, depending on the treatment. These recommendations were developed for U.S. care and require individual medical assessment rather than automatic application to every person.

This is a practical foundation for care that respects the person making the decision. Its value includes identifying unnecessary obstacles while preserving clinically important checks. A concise explanation can clarify those principles, but detailed decisions still depend on the full method-specific guidance and individual circumstances.